Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: K2 products are synthetic cannabinoid-laced, marijuana-like drugs of abuse, use of which is often associated with clinical symptoms atypical of marijuana use, including hypertension, agitation, hallucinations, psychosis, seizures and panic attacks. JWH-018, a prevalent K2 synthetic cannabinoid, is structurally distinct from Δ(9)-THC, the main psychoactive ingredient in marijuana. Since even subtle structural differences can lead to differential metabolism, formation of novel, biologically active metabolites may be responsible for the distinct effects associated with K2 use. The present study proposes that K2's high adverse effect occurrence is due, at least in part, to distinct JWH-018 metabolite activity at the cannabinoid 1 receptor (CB1R). METHODS/PRINCIPAL FINDINGS: JWH-018, five potential monohydroxylated metabolites (M1-M5), and one carboxy metabolite (M6) were examined in mouse brain homogenates containing CB1Rs, first for CB1R affinity using a competition binding assay employing the cannabinoid receptor radioligand [(3)H]CP-55,940, and then for CB1R intrinsic efficacy using an [(35)S]GTPγS binding assay. JWH-018 and M1-M5 bound CB1Rs with high affinity, exhibiting K(i) values that were lower than or equivalent to Δ(9)-THC. These molecules also stimulated G-proteins with equal or greater efficacy relative to Δ(9)-THC, a CB1R partial agonist. Most importantly, JWH-018, M2, M3, and M5 produced full CB1R agonist levels of activation. CB1R-mediated activation was demonstrated by blockade with O-2050, a CB1R-selective neutral antagonist. Similar to Δ(9)-THC, JWH-018 and M1 produced a marked depression of locomotor activity and core body temperature in mice that were both blocked by the CB1R-preferring antagonist/inverse agonist AM251. CONCLUSIONS/SIGNIFICANCE: Unlike metabolites of most drugs, the studied JWH-018 monohydroxylated compounds, but not the carboxy metabolite, retain in vitro and in vivo activity at CB1Rs. These observations, combined with higher CB1R affinity and activity relative to Δ(9)-THC, may contribute to the greater prevalence of adverse effects observed with JWH-018-containing products relative to cannabis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922 · cited 1×
“The Cheng-Prusoff equation [61] was used to convert the experimental IC50 values obtained from competition receptor binding experiments to Ki values, a quantitative measure of receptor affinity.”
MethodCannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 1×
“CB1Rs are endogenously expressed in abundant quantities in the CNS, while negligible levels of CB2 receptors are present [25,26].”
BackgroundGaliègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D., LE Fur, G., & Casellas, P. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20780.x · Cited by 1,749 · cited 1×
“CB1Rs are endogenously expressed in abundant quantities in the CNS, while negligible levels of CB2 receptors are present [25,26].”
BackgroundPertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605 · cited 1×
“0 nM, respectively [29,30].”
‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?
Auwärter, V., Dresen, S., Weinmann, W., Müller, M., Pütz, M., & Ferreirós, N. (2009) · Journal of Mass Spectrometry · doi:10.1002/jms.1558 · Cited by 660 · cited 2×
“and tolerable side effects in most users, such as appetite stimulation and orthostatic hypotension, it very rarely causes the adverse effects observed rather commonly with similar use of K2 products, such as hypertension, agitation, hallucinations, psychoses, seizures and panic attacks [1,4,12,13].”
BackgroundShowalter, V. M., Compton, D. R., Martin, B. R., & Abood, M. E. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20744-3 · Cited by 571 · cited 1×
“JWH-018 activates CB1Rs with greater potency and efficacy than D(9)-THC [10,20].”
BackgroundVoltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders
Mantegazza, M., Curia, G., Biagini, G., Ragsdale, D. S., & Avoli, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70059-4 · Cited by 455 · cited 1×
“Therefore, seizures caused by K2 are possibly due to the antagonism of other inhibitory networks, such as GABA channels [49], and/or the activation of excitatory networks, such as metabotropic glutamate receptors (mGluRs) [50], Na channels [51], and Ca channels [43].”
BackgroundDopaminergic dysfunction in schizophrenia: Salience attribution revisited
Heinz, A., & Schlagenhauf, F. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq031 · Cited by 412 · cited 1×
“Theories underlying the neurobiological mechanisms of hallucinations and psychosis include abnormal dopaminergeric neurotransmission, as described in the dopamine hypothesis of schizophrenia [52], serotonergic transmission, as seen with the serotonergic classical hallucinogens [53], and NMDA glutamate receptor blockad…”
BackgroundMultiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 411 · cited 1×
“Theories underlying the neurobiological mechanisms of hallucinations and psychosis include abnormal dopaminergeric neurotransmission, as described in the dopamine hypothesis of schizophrenia [52], serotonergic transmission, as seen with the serotonergic classical hallucinogens [53], and NMDA glutamate receptor blockad…”
BackgroundThe pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice.
Smith, P. B., Compton, D. R., Welch, S. P., Razdan, R. K., Mechoulam, R., & Martin, B. R. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22356-4 · Cited by 393 · cited 1×
“the cannabinoid ‘‘tetrad’’ [32]).”
Cited by
Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications
Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R. L., Pirard, S., & Huestis, M. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.005 · Cited by 709
Seely, K. A., Lapoint, J., Moran, J. H., & Fattore, L. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.04.017 · Cited by 465
Self-citationBeyond THC: The New Generation of Cannabinoid Designer Drugs
Fattore, L., & Fratta, W. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00060 · Cited by 443
Spicing things up: synthetic cannabinoids
Spaderna, M., Addy, P. H., & D’Souza, D. C. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3188-4 · Cited by 296
Fantegrossi, W. E., Moran, J. H., Radominska-Pandya, A., & Prather, P. L. (2014) · Life Sciences · doi:10.1016/j.lfs.2013.09.017 · Cited by 261
Self-citationBanister, S. D., Stuart, J., Kevin, R. C., Edington, A., Longworth, M., Wilkinson, S. M., Beinat, C., Buchanan, A. S., Hibbs, D. E., Glass, M., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00107 · Cited by 197
Novel halogenated derivates of JWH-018: behavioral and binding studies in mice
Vigolo, A., Ossato, A., Trapella, C., Vincenzi, F., Rimondo, C., Seri, C., Varani, K., Serpelloni, G., & Marti, M. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.02.008 · Cited by 91
Emergence and properties of spice and bath salts: a medicinal chemistry perspective
Lewin, A. H., Seltzman, H. H., Carroll, F. I., Mascarella, S. W., & Reddy, P. A. (2014) · Life Sciences · doi:10.1016/j.lfs.2013.09.026 · Cited by 72
Barbieri, M., Ossato, A., Canazza, I., Trapella, C., Borelli, A. C., Beggiato, S., Rimondo, C., Serpelloni, G., Ferraro, L., & Marti, M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.06.027 · Cited by 56
Metadata
- Authors
- Brents, L. K., Reichard, E. E., Zimmerman, S. M., Moran, J. H., Fantegrossi, W. E., & Prather, P. L.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-07-06
- Volume
- 6
- Issue
- 7
- Pages
- e21917
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2038784126
- Cited by
- 214
- References
- 55
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.